VVT Medical (TSXv:VVTM) develops, manufactures, and markets minimally invasive, non-thermal solutions for venous disease treatments. Its devices, ScleroSafe and V-Block, are commercially available worldwide. VVT's proprietary dual-mode technology delivers safe, efficient, and anesthesia-free procedures.
With global adoption accelerating, VVT is positioned for growth in the expanding non-thermal vein care market.
Investor relations
Proven technology.
Expanding markets.
Growing value.
Proven technology.
Expanding markets. Growing value.
A vast, untapped market
40M
Americans suffer from symptomatic varicose veins
5%
Patients seek treatment
<3%
Are actually treated
$1.3B
Spent annually in the US
$60B
Total addressable market
Source: Alzheimer's Association 2020, ACS Cancer facts and figures 2020, Virnai SS. Circulation 2020;141:e139–e569, CDC National Diabetes Statistic report 2020, Yost CLI Suppl 2016 THE SAGE GROUP and Yost ML Chronic Venous Disease THE SAGE